Loading
Signaling Pathways in Disease / Nuclear Receptors and Signaling / Cancer Related Gene Regulation · Journal article
Nature Communications · September 5, 2026
Encouraging direction, but not yet definitive.
PRMT7 deletion or pharmacologic inhibition via PROTAC degrader MS54 activates NF-κB signaling in CD8+ T cells, enhancing proliferation, activation markers, cytokine production and cytotoxic function in vitro and improving tumor control in a mouse melanoma model. This identifies PRMT7 as a negative regulator of anti-tumor T cell immunity and MS54 as a candidate to enhance adoptive T cell therapy, but efficacy is demonstrated in a single syngeneic tumor model and human studies remain ex vivo.
Mechanistic study combining T cell-specific genetic deletion, PROTAC inhibitor, mouse syngeneic tumor model, and ex vivo human CTL assays. CD8+ T cells from Prmt7-deficient mice, OT-I transgenic CTLs, and human CTL; tumor model: syngeneic melanoma in mice. Intervention: Prmt7 deletion (via CD4-Cre transgene) or PRMT7 PROTAC degrader MS54 treatment of CD8+ T cells. Compared with: Wild-type or vehicle-treated CD8+ T cells.
Prmt7 deletion increases CD8+ T cell effector differentiation, cytokine secretion, cytolytic activity and anti-tumor responses Prmt7 deficiency activates NF-κB pathway and boosts expression of CD25, CD69 and IFNγ PRMT7-targeting PROTAC degrader MS54 activates NF-κB pathway similarly to Prmt7-deficient CTL in vitro
In human CTL, MS54 enhances proliferation, CD69 and CD137 expression, IFNγ production and cytotoxicity toward melanoma
The findings suggest PRMT7 inhibition via MS54 could enhance adoptive T cell therapy efficacy by augmenting CD8+ T cell expansion and effector function. Clinical translation requires controlled trials in human patients with cancer.
A mechanistically sound study combining genetic and pharmacological approaches in mouse and human models, demonstrating PRMT7 inhibition enhances CD8+ T cell function, but limited by single tumor model and lack of phase-controlled clinical trial.
As stated by the source record.
Quoted from the source exactly as published.
The findings suggest PRMT7 inhibition via MS54 could enhance adoptive T cell therapy efficacy by augmenting CD8+ T cell expansion and effector function. Clinical translation requires controlled trials in human patients with cancer.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Successful cellular immunotherapy for cancer utilising cytotoxic T lymphocytes (CTL) requires efficient expansion while maintaining effector function. Understanding how CTL expansion and function are regulated during the cell preparation process is thus important. Here, we show that T cell-specific deletion of Prmt7 using CD4-Cre increases CD8+ T cell effector differentiation, cytokine secretion, cytolytic activity and anti-tumor responses. Prmt7 deficiency transcriptionally reprograms CD8+ T cells by activating the NF-κB pathway, boosting proliferation, and facilitating the production of effector molecules such as CD25, CD69 and IFNγ. Mechanistically, PRMT7 associates with RelA and restricts RelA nuclear translocation. In vitro, a self-developed PRMT7-targeting PROTAC degrader, MS54, similarly activates the NF-κB pathway as in Prmt7-deficient CTL. In vivo, adoptive cell transfer of MS54-treated OT-I CTLs improves tumor control in a mouse syngeneic melanoma model. In human CTL, MS54 enhances proliferation, activation markers (CD69, CD137) expression, IFNγ production and cytotoxicity toward melanoma. Our findings thus identify PRMT7 as a negative regulator of CD8+ T cell immunity and highlight MS54 as a potential strategy to improve adoptive T cell therapy. Cytotoxic T cells (CTL) are successfully employed in tumour therapy but understanding how their expansion and effector function is regulated might result in further improvements. Here the authors show by a T-cell-specific deletion of Prmt7 and by developing a PRMT7-targeting PROTAC degrader that PRMT7 is a negative regulator of the NF-κB pathway in CTL, removing of which improves anti-tumour function of CTL.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.